Especially in view of the emerging cardiometabolic phenotypes (obesity, type 2 diabetes mellitus, and hypertension), GLP-1RA and SGLT2-Is are receiving increasing attention as potential therapeutic strategies in HFpEF because of their glucose-lowering, anti-inflammatory, and anti-remodeling effects. Here, SLC5A2 is linked to type 2 diabetes mellitus.